11 Jun, 2024 Court Orders Patents Delisted from Orange Book: Is FTC's Newly Aggressive Posture Having an Impact? By Ross Blau Over the past year, FTC has placed two sets of Orange Book listings in its crosshairs, but, to date, FTC has not actually begun any...
30 Apr, 2024 FTC Expands Orange Book Patent Listing Challenges By Matt Murphy Ross Blau As discussed in November and December, the FTC has placed improper Orange Book patent listings squarely in its crosshairs. Initially,...
06 Feb, 2024 Lights, Camera, Action: GoPro’s Section 101 Arguments Head to the Federal Circuit By Rebecca Clegg Ross Blau Tomorrow, the Federal Circuit will hear oral argument in Contour IP Holding LLC v. GoPro, Inc., Case Nos. 2022-1654, -1691, once again...
15 Dec, 2023 The Inflation Reduction Act’s First Potential Impact on Biosimilars By Ted Mathias Ross Blau Chantelle Ankerman On October 31, 2023, FDA approved Amgen’s Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Janssen’s Stelara...
14 Dec, 2023 FTC Spoke, Kaleo and Impax Listened: Orange Book Patent Delistings Begin By Ross Blau As discussed last month, the FTC sent letters to 10 pharmaceutical companies, asserting that their listing of over 100 patents in FDA’s...
13 Nov, 2023 No Voluntary Delistings or Disputes in FDA's Orange Book Update By Matt Murphy Ross Blau FTC recently placed improper Orange Book patent listings squarely in its crosshairs. In its September 2023 policy statement, FTC...